Recent Updates
Recently added Catalysts

Eosinophilic Esophagitis: two biotech companies racing to a treatment

Immunology & InflammationOrphan cornerData as of 2026-09-04

Competitors2in the clinic
Median market cap$610Muniverse median $1.20B
Allocated capital$1.2B$1.2B competing
Phase 3 or filed01 mid, 1 early
Pure plays2this indication only
Capital rank132/299crowding rank 89

Eosinophilic Esophagitis is a two-horse race: Phathom Pharmaceuticals (PHAT, $732M) against Eupraxia Pharmaceuticals (EPRX, $488M).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $1.2B of allocated capital sits on the pair.

PHAT carries 60% of the $1.2B competing here, so the pair is far from evenly matched.

$1.2B of allocated capital sits in Eosinophilic Esophagitis, 132nd of 299 indications, and 2 of the 2 companies are pure plays that trade on this indication alone.

Companies developing drugs for Eosinophilic Esophagitis 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
PHATPhathom PharmaceuticalsVonoprazanPhase 21$732MYes1 31 Dec 2026
EPRXEupraxia PharmaceuticalsEP-104GIPhase 11$488MYes1 30 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. PHAT holds 60% of the $1.2B competing in this indication.

Why Eosinophilic Esophagitis is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Eosinophilic Esophagitis has 2 competitors and a median of $610M.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Pruritus2 companies · $1.2B · median $1.6BConcentrated betModerate to Severe Atopic Dermatitis1 company · $1.3B · median $2.6BUncontestedAutoimmune Pulmonary Alveolar Proteinosis1 company · $1.1B · median $1.1BUncontestedChronic Spontaneous Urticaria1 company · $1.0B · median $3.1BUncontestedImmunoglobulin A Nephropathy1 company · $1.6B · median $6.3BUncontestedPeanut Allergy1 company · $861M · median $861MUncontestedCeliac Disease1 company · $788M · median $1.6BUncontestedANCA-associated Vasculitis2 companies · $1.7B · median $3.3BConcentrated bet

Eosinophilic Esophagitis pipeline questions

Which biotech companies are developing drugs for Eosinophilic Esophagitis?

Phathom Pharmaceuticals (PHAT, Vonoprazan, Phase 2); Eupraxia Pharmaceuticals (EPRX, EP-104GI, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Eosinophilic Esophagitis.

How advanced is the Eosinophilic Esophagitis pipeline?

Of the 2 clinical-stage programmes in Eosinophilic Esophagitis, 0 are in Phase 3 or filed, 1 is in mid-stage development and 1 is in early-stage development.

Which company leads the Eosinophilic Esophagitis field?

PHAT is the largest developer in Eosinophilic Esophagitis, holding 60% of the $1.2B of market capitalisation competing in the indication. The median competitor is worth $610M.

When is the next Eosinophilic Esophagitis catalyst?

The next dated catalyst in Eosinophilic Esophagitis is EPRX on 30 Sep 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map